Meeting
2019 ASCO Annual Meeting
Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis.
Authors
Hiroe Kayatani
Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
Hiroe Kayatani , Keisuke Aoe , Kadoaki Ohashi , Hiroshige Yoshioka , Akihiro Bessho , Nobuhisa Ishikawa , Masahiro Yamasaki , Toshiyuki Kozuki , Nobukazu Fujimoto , Yutaka Ueda , Syuuji Bandoh , Isao Murakami , Hirohisa Ichikawa , Tetsuya Kubota , Keisuke Sugimoto , Nagio Takigawa , Takashi Sumikawa , Katsuyuki Kiura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9056)
DOI
10.1200/JCO.2019.37.15_suppl.9056
Abstract #
9056
Poster Bd #
379
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.
First Author: Joop De Langen
Poster
2022 ASCO Annual Meeting
Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
First Author: Akito Hata
Poster
2018 ASCO Annual Meeting
An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: A Precision trial of the Belgian Society of Medical Oncology.
First Author: Lore Decoster
Poster
2018 ASCO Annual Meeting
Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.
First Author: Marcelo Vailati Negrao